Form 8-K - Current report:
SEC Accession No. 0000950170-22-023510
Filing Date
2022-11-09
Accepted
2022-11-09 07:16:30
Documents
14
Period of Report
2022-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K scyx-20221109.htm   iXBRL 8-K 76701
2 EX-99.1 scyx-ex99_1.htm EX-99.1 243711
3 GRAPHIC img135655574_0.jpg GRAPHIC 3723
  Complete submission text file 0000950170-22-023510.txt   460403

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT scyx-20221109_lab.xml EX-101.LAB 13540
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT scyx-20221109.xsd EX-101.SCH 2464
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT scyx-20221109_pre.xml EX-101.PRE 10937
8 EXTRACTED XBRL INSTANCE DOCUMENT scyx-20221109_htm.xml XML 4696
Mailing Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548
Business Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 201-884-5485
SCYNEXIS INC (Filer) CIK: 0001178253 (see all company filings)

EIN.: 562181648 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36365 | Film No.: 221370645
SIC: 2834 Pharmaceutical Preparations